In a study published in the journal Blood Advances, researchers report the first proof that infusions of an engineered protein into mice, called mycoadhesive protein 3 (MPM-3) full-length, can boost the prognosis of patients with MDS/MS.
In a few years’ time they will not only fight viral infections but also fight acute radiation infections such as acute radiation from the surgical scalpel,” says senior author Dr.
Jumping-jong-sensei Tsuda, from the Lung Cancer Centre at the National Cancer Center of the University of Tokyo.
Stimulation of MDS/MS bone marrow stem cells by MPM-3 was employed to promote the regeneration of their blood supply.